ANTERIOS
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $7.5m | Series A | |
N/A | $5.2m | Early VC | |
N/A | $1.5m | Early VC | |
N/A | $750k | Early VC | |
N/A | $2.0m | Early VC | |
N/A | $3.0m | Early VC | |
N/A | $4.7m | Early VC | |
N/A | N/A | IPO | |
$90.0m Valuation: $90.0m | Acquisition | ||
Total Funding | €22.4m |
Related Content
Recent News about ANTERIOS
EditAnterios Inc. operates in the biopharmaceutical industry, focusing on developing innovative treatments for some of the most challenging health conditions. The company serves a diverse range of clients, including healthcare providers, hospitals, and patients in need of advanced medical solutions. Anterios Inc. operates in a highly regulated market, adhering to stringent legal and ethical standards to ensure the safety and efficacy of its products. The business model is centered around research and development (R&D), where significant investments are made to discover and develop new drugs. Revenue is generated through the sale of these pharmaceutical products, licensing agreements, and partnerships with other healthcare organizations. The company aims to make a remarkable impact on people's lives by not only treating diseases but also improving overall health outcomes.
Keywords: biopharmaceutical, innovative treatments, healthcare providers, hospitals, patients, regulated market, R&D, drug discovery, licensing, health outcomes.